Dyslipidemia – challenges and news in treatment

Abstract:

Despite the overwhelming evidence of the treatment for dyslipidaemia reducing CV risk and despite the presence of proven effective medicines, many patients remain at high CV risk, primarily due to poor drug adherence, inadequate treatment, and a negative attitude towards the drugs, developed by both patients and physicians. This has been recognized in the recent guidelines of the European Cardiac Society (ESC), which places great emphasis on aggressive treatment of dyslipidaemia, achieving even lower LDL cholesterol targets than in earlier recommendations, especially in those who have very high risk of developing CVD - such as patients with established heart and blood vessels diseases. In addition to changing lifestyle habits and introducing statins as the cornerstone of therapy, the guidelines also provide clear recommendations for additional therapeutic strategies that include more recent drugs such as PCSK9 inhibitors. In a continuous contact with an individual, knowing all his CV risks and targeting them (personalized medicine) a GP can influence the improvement of CV risks. 

Key words:
dyslipidaemia; family medicine